New research presented at the June 2014 American Diabetes Association Scientific Sessions suggests that canola oil helps control blood glucose in people with Type 2 diabetes when it's incorporated into a low-glycemic index diet.
A study published Wednesday on JAMA's website found that diabetes patients taking metformin had a higher risk of all-cause death when insulin was added to their treatment as compared to when sulfonylureas were added to treatment.
More than 29 million people in the United States have diabetes, up from the previous estimate of 26 million in 2010, according to a report released Tuesday by the Centers for Disease Control and Prevention.
Dr. Robynne Chutkan is the founder of the Digestive Center for Women, an integrative gastroenterology practice in Chevy Chase, Maryland. She’s on the faculty at Georgetown Hospital, a former board member of the American Society for Gastrointestinal Endoscopy (ASGE), and the author of “Gutbliss: A 10-Day Plan to Ban Bloat, Flush Toxins, and Dump Your Digestive Baggage.”
New research published in Diabetologia, the journal of the European Association for the Study of Diabetes, found that brief bursts of intense exercise before meals — termed exercise "snacking" by the study authors — helps control blood sugar in people with insulin resistance more effectively than one daily 30-minute session of moderate exercise.
A multi-year medical research study released Thursday that examined health issues among U.S. Hispanic/Latino groups has yielded data indicating that less than half of the participants diagnosed with diabetes had the condition under control.
In a study released Saturday that included data from more than 3 million children and adolescents from diverse geographic regions of the United States, researchers found that the prevalence of both Type 1 and Type 2 diabetes increased significantly between 2001 and 2009.
Rates of five major diabetes-related complications have declined substantially in the last 20 years among U.S. adults with diabetes, according to a study by the Centers for Disease Control and Prevention, published in the current issue of the New England Journal of Medicine.
Cases of diabetes and pre-diabetes in the United States have nearly doubled since 1988, suggests new research released Tuesday from the Johns Hopkins Bloomberg School of Public Health, with obesity apparently to blame for the surge.
MannKind Corp. on Tuesday announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the Food and Drug Administration voted 13-to-1 to recommend that Afrezza (insulin human [rDNA origin]) inhalation powder be granted marketing approval by the FDA to improve glycemic control in adults with Type 1 diabetes and voted 14-to-0 to recommend that Afrezza be granted marketing approval by the FDA to improve glycemic control in adults with Type 2 diabetes.
At the American Pharmacists Association Convention on Thursday, PrescribeWellness announced a partnership with the APhA Foundation to provide community pharmacies new tools to help their diabetic patients improve their disease management and health.
In a study that included nearly 300,000 adults without a known history of diabetes or cardiovascular disease, adding information about glycated hemoglobin (HbA1c), a measure of longer-term blood sugar control, to conventional CVD risk factors like smoking and cholesterol was associated with little improvement in the prediction of CVD risk, according to a study in the March 26 issue of JAMA.
Study results announced Thursday by Novo Nordisk and collaborative partners found that participation in diabetes education is associated with a greater sense of well-being and the ability to self-manage diabetes.
AstraZeneca received approval from the Food and Drug Administration for its Bydureon pen (exenatide extended-release for injectable suspension) 2-mg, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.
An international team led by researchers at the Broad Institute and Massachusetts General Hospital has identified mutations in a gene that can reduce the risk of developing Type 2 diabetes, even in people who have such risk factors as obesity and old age, the group announced Sunday.
The Food and Drug Administration has approved Myalept (metreleptin for injection) to treat complications of leptin deficiency in patients with congenital generalized or acquired generalized lipodystrophy, a condition associated with a lack of fat tissue.
America’s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide, the Pharmaceutical Research and Manufacturers of America announced Tuesday.